Finoriq research workspace
BullFrog AI Holdings, Inc. (BFRG) Historical Metrics
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial. Review BFRG fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
- Company
- BullFrog AI Holdings, Inc. (BFRG)
- Ticker
- BFRG
- Market Cap
- $11.8M
- Latest Price
- $0.6382
- Industry
- Biotech & Pharma
BullFrog AI Holdings, Inc. (BFRG) Current Valuation Metrics
Static valuation preview for BullFrog AI Holdings, Inc. (BFRG). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 118x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -47.4% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -40.2% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 6.42x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.